(Adnkronos) - L'Agenzia Italiana del Farmaco (AIFA) ha recentemente approvato la rimborsabilità di pirtobrutinib, un nuovo farmaco per il trattamento del linfoma mantellare recidivato o refrattario. Questo tipo di tumore del sangue, che colpisce circa 860 persone ogni anno in Italia, ha origine dai linfociti B e spesso si manifesta nei linfonodi. Pirtobrutinib, prescritto dagli ematologi e assunto per via orale, rappresenta una svolta nel trattamento di pazienti che hanno già ricevuto un inibitore, ma che hanno visto la malattia ripresentarsi.
Category
🗞
NewsTranscript
00:00The Italian pharmaceutical agency has recently approved the reimbursement of Pirtobrutinib,
00:09a new drug for the treatment of lymphoma mantle.
00:13This type of blood tumor, which affects about 860 people every year in Italy, originates
00:19from lymphocytes and often manifests in lymph nodes.
00:22Pirtobrutinib, prescribed by hematologists and taken orally, represents a turn in the
00:28treatment of patients who have already received an inhibitor, but who have seen the disease
00:33reappear.
00:34This new inhibitor, Pirtobrutinib, so-called third-generation non-convulsive, helps us
00:40to treat these patients who otherwise would not have other therapeutic chances.
00:45I add that this new drug gives us the possibility of a complete and partial response
00:52over 50% with a good profile of toxicity.
00:55Pirtobrutinib is distinguished as the first and only inhibitor of reversible PTK approved
01:00in this type of patients, with an innovative action mechanism.
01:04Thanks to this peculiarity, it is able to restore a therapeutic response, solid and
01:09lasting, even in patients previously treated, with a global response rate of almost 57%,
01:16as emerged from the results of the Bruin clinical study.
01:20It is a drug that stands out for its innovative mechanism, compared to other PTK inhibitors,
01:30which are irreversible inhibitors, with a very vigorous action mechanism, Pirtobrutinib
01:40is a reversible inhibitor, therefore with a much more dynamic and flexible action mechanism,
01:48and which in any case continues to associate with a persistent inhibition of the molecular target.
01:56And this is important because from inhibition the therapeutic response descends.
02:01The drug, produced by Lilly, a company committed to research and development for 150 years,
02:07not only has shown excellent effectiveness, but has proven to be well tolerated, guaranteeing
02:12a better quality of life for patients often frail and elderly.
02:16In the last ten years we have seen a development of new therapies, new solutions for a better
02:24life of patients, for this reason we are also committed to finding solutions for these
02:30patients who are looking for time, time to be with their family, time to live their lives.
02:37And we are very proud today to be able to announce that Pirtobrutinib will be available
02:42for patients in Italy.
02:44Pirtobrutinib therefore marks a new era in the treatment of lymphoma, offering new
02:50hopes for those who are facing this disease.